Randomized controlled trial of favipiravir, hydroxychloroquine, and standard care in patients with mild/moderate COVID-19 disease
AlQahtani et al., Scientific Reports, doi:10.1038/s41598-022-08794-w
https://c19hcq.org/alqahtani2.html